Study questions HDL medication benefit

Share this article:

Drugs focused on increasing HDL levels (the “good cholesterol”) don't seem to do much to stave off heart attacks, strokes or death as much as has been hoped. Reuters reports that a small study showed the drugs did little in terms of death prevention regardless of whether they'd been taken before or after statins, a drug class which lowers LDL cholesterol levels (the “bad cholesterol”).

Cleveland Clinic cardiologist Steven Nissen tells Reuters the results should not encourage patients to stop taking their medications. Reuters notes that Nissen is heading up an Eli Lilly trial for a CETP inhibitor. CETPs are associated with low HDL levels. Inhibitors work to prevent this and are associated with elevated HDL levels.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.